Montreal Neurological Institute-Hospital

Montreal, Quebec H3A2B4

0 studies enrolling now · 9 studies all time

What they study most

Amyotrophic Lateral Sclerosis, C9orf72, Charcot-Marie-Tooth Disease, Dementia Frontotemporal, FTD, FTD-GRN, Facioscapulohumeral Muscular Dystrophy, Frontotemporal Dementia, Glioblastoma Multiforme, MSA, Parkinson's Disease, Parkinson's Disease (PD)

Studies at this site

• A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes — Running, not enrolling
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD — Running, not enrolling
• A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation — Stopped early
• Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma — Paused
• Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure — Stopped early
• Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure — Stopped early
• Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX) — Stopped early
• Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) — Stopped early
• Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS) — Stopped early